Loading...
OTCM
SPHRY
Market cap23mUSD
Jul 02, Last price  
0.59USD
1D
0.51%
1Q
0.00%
Jan 2017
-88.76%
IPO
-83.38%
Name

Starpharma Holdings Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
45.26
EPS
—
Div Yield, %
—
Shrs. gr., 5y
2.07%
Rev. gr., 5y
24.96%
Revenues
8m
+182.03%
2,049,298500863,8541,412,0002,019,0001,404,0001,144,000925,00020,0001,253,0001,697,0004,574,0003,647,0004,957,0002,720,0006,033,0001,798,0004,682,0002,939,0008,289,000
Net income
-8m
L-47.79%
-7,585,992-7,522,789-7,244,996-7,491,000-4,127,000-6,378,000-8,930,000-13,658,000-5,229,000-14,635,000-18,950,000-21,292,000-15,217,000-10,285,000-14,254,000-14,678,000-19,732,000-16,154,000-15,638,000-8,164,999
CFO
-7m
L-48.44%
-5,808,589-7,489,948-3,380,194-5,352,000-4,029,000-3,630,000-6,476,000-9,770,000-9,795,000-9,813,000-13,615,000-17,811,000-16,955,000-10,201,000-10,344,000-10,776,000-14,808,000-13,162,000-13,533,000-6,977,000
Earnings
Aug 20, 2025

Profile

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
URL
https://www.starpharma.com/
IPO date
Sep 28, 2000
Employees
45
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
8,289
182.03%
2,939
-37.23%
Cost of revenue
19,784
27,612
Unusual Expense (Income)
NOPBT
(11,495)
(24,673)
NOPBT Margin
Operating Taxes
(5,527)
(7,631)
Tax Rate
NOPAT
(5,968)
(17,042)
Net income
(8,165)
-47.79%
(15,638)
-3.19%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,571
5,522
Long-term debt
4,710
5,500
Deferred revenue
Other long-term liabilities
79
48
Net debt
(17,079)
(24,158)
Cash flow
Cash from operating activities
(6,977)
(13,533)
CAPEX
(89)
(621)
Cash from investing activities
(89)
(610)
Cash from financing activities
(4,747)
(695)
FCF
(6,376)
(18,276)
Balance
Cash
23,360
35,180
Long term investments
Excess cash
22,946
35,033
Stockholders' equity
28,116
34,815
Invested Capital
8,777
8,320
ROIC
ROCE
EV
Common stock shares outstanding
411,433
409,035
Price
0.10
-69.35%
0.31
-58.11%
Market cap
39,086
-69.18%
126,801
-57.89%
EV
22,007
102,643
EBITDA
(10,380)
(23,480)
EV/EBITDA
Interest
Interest/NOPBT